Groupama Asset Managment Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Groupama Asset Managment increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,339 shares of the biopharmaceutical company's stock after acquiring an additional 9,062 shares during the period. Groupama Asset Managment owned approximately 0.07% of Regeneron Pharmaceuticals worth $56,445,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Intact Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $356,000. Principal Financial Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Fagan Associates Inc. increased its holdings in Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the period. Golden State Equity Partners raised its position in Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after purchasing an additional 1,272 shares in the last quarter. Finally, ABC Arbitrage SA purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $1,510,000. 83.31% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Bank of America restated an "underperform" rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Finally, UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $14.96 on Thursday, hitting $610.64. 1,047,509 shares of the company's stock traded hands, compared to its average volume of 681,071. The firm's 50-day moving average price is $680.43 and its two-hundred day moving average price is $786.93. The firm has a market capitalization of $66.76 billion, a PE ratio of 15.95, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $605.56 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $11.86 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.